As of today, the treatment offers restricted distribution within Europe. Despite patient access programs have demonstrated therapeutic benefits for patients living with amyloidosis, broader commercial distribution has https://cag-cagrilintide-for-sal223819.activoblog.com/54487277/cagrilintide-it-european-markets-access